Shots:
Chiesi Group has entered into an exclusive global collaboration & license deal with Arbor for ABO-101 in primary hyperoxaluria type 1 (PH1) & a multitarget option to use Arbor’s gene editing platform for developing liver-targeted therapies for rare diseases
As per the deal, Chiesi will obtain exclusive rights to develop & commercialize ABO-101 for PH1…
